USP Analysis of Glimepiride on an Alliance HPLC System: Modernization of a USP Method

Significance of the Topic

The United States Pharmacopeia (USP) maintains many legacy HPLC methods that reliably meet system suitability criteria but often involve long runtimes, high solvent consumption, and resource-intensive operations. Modernizing these assays on existing instrumentation enhances laboratory efficiency, reduces analysis time, and supports sustainability goals without compromising analytical performance.

Objectives and Study Overview

This study evaluates the USP glimepiride assay using an Alliance HPLC system and applies USP Chapter <621> guidelines to scale the method for higher throughput. The goal was to compare the official monograph conditions with a miniaturized, faster variant while ensuring compliance with resolution and precision requirements.

Methodology and Used Instrumentation

Common chromatographic conditions included an Alliance e2695 pump, 2998 photodiode array detector, 10 mm flow cell, and Empower 3 FR2 data system. The mobile phase consisted of monobasic sodium phosphate buffer (pH 2.1–2.7) mixed with acetonitrile. Samples and standards were prepared per the USP glimepiride monograph.

• Original method: XBridge BEH C18, 5 µm, 4.6×250 mm, 1.2 mL/min, 20 µL injection, 30 min runtime
• Scaled method: XBridge BEH C18, 3.5 µm, 4.6×150 mm, 1.71 mL/min, 12 µL injection, 13 min runtime
• Scaling calculations performed with ACQUITY UPLC Columns Calculator

Main Results and Discussion

Both the original and scaled assays met USP system suitability criteria:

• Resolution between related compounds B and C ≥ 4.0 (4.6 original, 4.0 scaled)
• Retention time RSD ≤ 2.0% (0.11% original, 0.05% scaled)
• Peak area RSD ≤ 2.0% (0.25% original, 0.27% scaled)

The scaled method reduced runtime by over 50% and halved solvent consumption. Stability testing over 3.25 hours with bracketed standard injections confirmed consistent performance (retention time RSD 0.22%, area RSD 0.31%). The assay quantified glimepiride drug substance at 99.67% purity.

Benefits and Practical Applications

By following USP <621> scaling rules, laboratories can update legacy methods on conventional HPLC systems to achieve:

• Increased sample throughput
• Reduced solvent use and cost
• Shorter analysis times without new instrumentation

Future Trends and Applications

Ongoing trends include wider adoption of UPLC for even higher speed and resolution, integration of automated method translation tools, and greener solvent systems. Enhanced software calculators and predictive modeling will further streamline method modernization across pharmaceutical assays.

Conclusion

The case study demonstrates that USP glimepiride assays can be effectively modernized on an Alliance HPLC platform. Method scaling delivered significant runtime and solvent savings while maintaining required resolution and precision, illustrating a practical path for updating legacy pharmacopeial methods.

References

1. United States Pharmacopeia and National Formulary. Chapter <621> Chromatography. USP38–NF33 S1. 2015, p. 424.
2. United States Pharmacopeia and National Formulary. Glimepiride Official Monographs. USP38–NF33 S1. 2015, p. 3671.